Journey Medical Q2 Adj EPS $(0.04) Beats $(0.33) Estimate, Sales $17.17M Beat $14.81M Estimate
Portfolio Pulse from vinayak@benzinga.com
Journey Medical (NASDAQ:DERM) reported Q2 adjusted EPS of $(0.04), beating the estimate of $(0.33) by 87.88%. This is a 73.33% increase over losses from the same period last year. The company also reported quarterly sales of $17.17M, beating the estimate of $14.81M by 15.95%, but this is a 6.12% decrease over sales from the same period last year.
August 08, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Journey Medical's Q2 results exceeded estimates, which could positively impact the stock in the short term.
Journey Medical reported better than expected Q2 results, with both EPS and sales beating estimates. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100